<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503266</url>
  </required_header>
  <id_info>
    <org_study_id>MT-7117-E02</org_study_id>
    <secondary_id>2017-004549-25</secondary_id>
    <nct_id>NCT03503266</nct_id>
  </id_info>
  <brief_title>Mass Balance Study With MT-7117</brief_title>
  <acronym>MT-7117 MB</acronym>
  <official_title>An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-7117 After a Single Oral Dose to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Development America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Development America, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, open-label, mass balance study in healthy male subjects utilising a
      single oral dose of [14C] MT 7117.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2018</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open Label</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax - maximum observed plasma concentration (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax - time at which Cmax occurs (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0 t - area under the plasma concentration time curve from time zero to the last measurable concentration (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ - area under the plasma concentration-time curve from time zero to infinity (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t½ - apparent terminal elimination half-life (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Kel - terminal elimination rate constant (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F - apparent clearance (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>VZ/F - apparent volume of distribution (plasma and whole blood)</measure>
    <time_frame>at pre-dose and up to 168 hours post-dose. If collection is extended up to Day 14: at up to 312 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in urine and faeces</measure>
    <time_frame>Day -1 and up to 168 hours post-dose. If collection is extended up to Day 14: up to 312 hours post-dose.</time_frame>
    <description>Ae (urine), Ae (faeces) and Ae (total): amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total radioactivity in urine and faeces</measure>
    <time_frame>Day -1 and up to 168 hours post-dose. If collection is extended up to Day 14: up to 312 hours post-dose.</time_frame>
    <description>%Ae (urine), %Ae (faeces) and %Ae (total): amount excreted and cumulative amount excreted in urine, faeces and total (urine and faeces combined) expressed as a percentage of the dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by incidence of adverse events (AEs) and serious AEs</measure>
    <time_frame>Up to 14 Days after dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>[14C] MT-7117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14-C MT-7117</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C] MT-7117</intervention_name>
    <description>14-C MT-7117</description>
    <arm_group_label>[14C] MT-7117</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Able to provide written informed consent to participate in this study after reading
             the participant information sheet and Informed Consent Form, and after having the
             opportunity to discuss the study with the Investigator or designee.

          -  2. Caucasian male subjects aged 30 to 65 years (inclusive) at Screening.

          -  3. Healthy and free from illness or disease as determined by medical history, physical
             examination, electrocardiogram (ECG), vital signs, laboratory and other tests at
             Screening and Day -1, unless deemed not clinically significant by the Investigator or
             designee.

          -  4. Body weight of 60 to 110 kg (inclusive) and a body mass index (Quetelet index)
             ranging from 18 to 32 kg/m2 (inclusive) at Screening and Day -1.

          -  5. Vital signs within the following ranges at Screening and Day -1:

               -  Systolic blood pressure: 90 to 140 mmHg

               -  Diastolic blood pressure: 50 to 90 mmHg

          -  6. Subjects and partners agree to use contraception throughout the study, as defined
             in the Protocol body.

          -  7. Able to understand, in the Investigator's opinion, the nature of the study and any
             risks involved in participation and willing to cooperate and comply with the Protocol
             restrictions and requirements.

          -  8. Regular daily bowel movements (i.e., production of at least one stool per day).

        Exclusion Criteria:

          -  1. Presence or history of severe adverse reaction or allergy to any medicinal product
             that is of clinical significance.

          -  2. Participated in more than three clinical studies of a new chemical entity in the
             previous year or participated in a clinical study of any IMP within 12 weeks or five
             half-lives (whichever is longer) before the administration of IMP in this clinical
             study.

          -  3. Consumption of any food-supplements, prescribed or over the counter medicine
             (including herbal and dietary supplements, such as St. John's Wort) during the 7 days
             (or 14 days if the medicine is a potential enzyme inducer) or five half-lives
             (whichever is longer) before the administration of IMP and during the study, unless in
             the opinion of the Sponsor and the Investigator, the medication will not interfere
             with the objectives of the study or compromise the subject's safety (Note: The use of
             acetaminophen [2 g/day for up to 3 consecutive days] will be permitted from Screening
             and during the study).

          -  4. Clinically significant (in the opinion of the Investigator) endocrine, thyroid,
             hepatic (including Gilbert's syndrome), respiratory, gastrointestinal or renal
             disease, diabetes mellitus (type I and II), coronary heart disease, hypertension, or
             significant history of any psychiatric/psychotic disorder (including anxiety,
             depression and reactive depression).

          -  5. Clinically relevant abnormal medical history, physical findings or laboratory
             values at Screening or Day -1 that could interfere with the objectives of the study or
             the safety of the subject, as judged by the Investigator.

          -  6. Subjects with aspartate aminotransferase or alanine aminotransferase ≥2 x upper
             limit of normal or bilirubin above reference range at Screening or Day -1, confirmed
             by a repeat test at each visit.

          -  7. Has a positive hepatitis B surface antigen, hepatitis B core antibody, hepatitis C
             virus antibody, or human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2)
             result at Screening.

          -  8. Clinically significant abnormal 12-lead ECG findings, including subjects with
             corrected QT interval using Fridericia's formula (QTcF) of &gt;450 ms, or presence of
             atrial fibrillation or other significant arrhythmia at Screening or Day -1, confirmed
             by repeat assessment.

          -  9. Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of drugs or which may jeopardise the subject in
             case of participation in the study. The Investigator should be guided by evidence of
             any of the following:

               -  history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or
                  rectal bleeding;

               -  history of major gastrointestinal tract surgery such as gastrectomy,
                  gastroenterostomy or bowel resection;

               -  history or clinical evidence of pancreatic injury or pancreatitis.

          -  10. Excessive consumption of food or drink containing caffeine, including coffee, tea,
             cola, energy drinks or chocolates (&gt;5 cups of coffee or equivalent per day).

          -  11. Consumption of food or drink containing grapefruit, poppy seeds or Seville oranges
             from 7 days before the administration of the IMP.

          -  12. Presence or history (in the last 2 years) of alcohol abuse or weekly alcohol
             intake of more than 28 units (224 g) or a positive urine or breath alcohol test at
             Screening or Day 1. One unit (8 g) is equivalent to a ½ pint (280 mL) of beer, 1
             measure (25 mL) of spirits or 1 small glass (125 mL) of wine.

          -  13. Presence or history of drug abuse (as defined by Diagnostic and Statistical Manual
             of Mental Disorders [DSM-V] criteria) or a positive urine test for drugs of abuse at
             Screening or Day -1.

          -  14. Donation of one or more units of blood (450 mL) within 3 months before the
             administration of the IMP, or plasma within 7 days prior to Screening, or platelets
             within 6 weeks prior to Screening or the intention to donate blood within 3 months
             after the final study visit.

          -  15. Use of tobacco or nicotine-containing products (snuff, chewing tobacco, cigars,
             pipes, e cigarettes or nicotine replacement products) within the 3 month period prior
             to administration of IMP, during the confinement period and until the final study
             visit, or positive urine cotinine test at Screening or Day -1.

          -  16. Heavy physical training or excessive exercise (e.g., long distance running, weight
             lifting or any physical activity to which the subject is not accustomed) from 7 days
             before the administration of IMP, during the participation in the study and for 7 days
             prior to any outpatient visit.

          -  17. Family history of long QT syndrome or Torsades de Pointes.

          -  18. Subjects with poor peripheral venous access.

          -  19. Subjects who had a major surgical procedure or significant traumatic injury within
             14 days prior to Day -1, or anticipation of the need for major surgery during the
             study period.

          -  20. Subjects with creatinine clearance &lt;60 mL/minute (calculated using Cockcroft-Gault
             formula) at Screening.

          -  21. History of irritable bowel syndrome or other manifestation of abnormal bowel habit
             (e.g., diarrhoea, constipation).

          -  22. Previous exposure to MT-7117 before the administration of IMP in this study.

          -  23. Radiation exposure, including that from the present study, excluding background
             radiation but including diagnostic x rays and other medical exposures, exceeding 5 mSv
             in the last 12 months or 10 mSv in the last 5 years. No occupationally exposed worker,
             as defined in the Ionising Radiation Regulations 1999, shall participate in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Europe Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitsubishi Tanabe Pharma Europe Ltd General Information, to prevent mis-communication,</last_name>
    <phone>please e-mail:</phone>
    <email>regulatory@mt-pharma-eu.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Centre</name>
      <address>
        <city>United Kingdom</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mass Balance Study with MT-7117</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

